800
Participants
Start Date
January 31, 2023
Primary Completion Date
January 31, 2025
Study Completion Date
February 28, 2025
Index test: Abbott ID NOW STREP A 2
The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
Reference standard test: Composite of culture and PCR-based tests based on a throat swab
"Throat samples will be obtained by use of a double-swab collection-transportation system :~* Swab #1 will be used to perform the rapid antigen detection test (see below)~* Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
Comparator test: Rapid antigen detection test (usual care)
As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
ACTIV, Saint-Maur-des-Fossés
Centre Hospitalier Intercommunal Creteil
OTHER
Hôpital Necker-Enfants Malades
OTHER
University Hospital, Paris
OTHER
Groupe Hospitalier Diaconesses Croix Saint-Simon
OTHER
Association Clinique Thérapeutique Infantile du val de Marne
OTHER